CDK2 Overview
Novel Molecular Glue (MG) Degrader


                                                • CDK2 is a master regulator of           • Unlike inhibitors, CDK2
                 Potential best-in-class          the cell cycle with strong genetic        molecular glue degraders
                 profile, with exquisite          and clinical validation and broad         selectively degrade CDK2 while
                 selectivity for CDK2             oncology treatment potential              sparing closely related kinases
                                                  including breast cancer and               like CDK1, offering a potentially
                                                  other solid tumors                        broader therapeutic index



  OPPORTUNITY
                                                                                       CDK2 MGs offer an oral therapeutic
• ~500k potential patient         • CDK4/6 inhibitor class ~$13B in WW                 option with the potential to selectively
  impact in multiple tumor          revenue in 2024; projected to grow to              target cancer cells with minimal
  types1                            $18B by 20302                                      impact on healthy tissue



                  • Partnered with Gilead to accelerate development and commercialization, with up to $750 million in total
                    payments, including $85 million in upfront and potential option exercise payments
    STATUS
                  • Kymera will lead all research activities for the CDK2 MG program
                                                                                                                                  52
